Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics

Aldeyra Therapeutics, Inc. (ALDX)

Today's Latest Price: $7.59 USD

0.49 (6.90%)

Updated Oct 22 4:00pm

Add ALDX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ALDX Stock Price Chart Interactive Chart >

Price chart for ALDX

ALDX Price/Volume Stats

Current price $7.59 52-week high $8.70
Prev. close $7.10 52-week low $1.48
Day low $7.03 Volume 753,500
Day high $7.68 Avg. volume 726,544
50-day MA $6.97 Dividend yield N/A
200-day MA $5.04 Market Cap 293.22M

Aldeyra Therapeutics, Inc. (ALDX) Company Bio

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.

ALDX Latest News Stream

Event/Time News Detail
Loading, please wait...

ALDX Latest Social Stream

Loading social stream, please wait...

View Full ALDX Social Stream

Latest ALDX News From Around the Web

Below are the latest news stories about Aldeyra Therapeutics Inc that investors may wish to consider to help them evaluate ALDX as an investment opportunity.

Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., Chief Financial Officer Joshua Reed, and Chief Commercial Officer David McMullin will be participating in a fireside chat and hosting one-on-one meetings at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit, which is being held in a virtual format. The fireside chat is scheduled to begin at 2:30 p.m. ET Wednesday, September 23,

Business Wire | September 16, 2020

Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences: H.C. Wainwright 22nd Annual Global Investment Conference Presentation Date: Monday, September 14, 2020 Time: 3:30 p.m. ET 2020 Cantor Global Virtual Healthcare Conference Presentation Date: Wednesday, September 16, 2020 (Fireside Chat) Time: 2:40 p.m. ET A live webcast of the presen

Business Wire | September 10, 2020

Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in an ophthalmology panel discussion during Citi’s 15th Annual BioPharma Virtual Conference, taking place September 8-11, 2020. In addition, Aldeyra’s senior management will host one-on-one meetings at the conference. Panel Details Title: Seeing 20/20 in 2020 Date: Thursday, September 10, 2020 Time: 9:50 a.

Business Wire | September 3, 2020

Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem

Introduction Allergy has become a rising problem in the 21st century. While this might be caused by our rapid change to live in more crowded and larger cities, the real factors are still in research. However, the numbers are steadily increasing, and shockingly, 50% of school children have been found...

Tien Duy Vo on Seeking Alpha | September 2, 2020

Aldeyra Therapeutics (ALDX) Investor Presentation - Slideshow

The following slide deck was published by Aldeyra Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | August 6, 2020

Read More 'ALDX' Stories Here

ALDX Price Returns

1-mo 11.95%
3-mo 8.74%
6-mo 194.19%
1-year 32.69%
3-year 22.42%
5-year 21.25%
YTD 30.64%
2019 -30.00%
2018 22.06%
2017 27.10%
2016 -21.09%
2015 -6.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8533 seconds.